PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from India

Selling into Europe as a biologics and biosimilars maker from India

Your Indian team gets biosimilars into European hospitals without costly restarts.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • India, Biologics and biosimilarswho it is written for

Why this training matters

The Committee for Medicinal Products for Human Use sends its list of questions at day 120, and your team finds a gap in the comparability data. The clock stops, the launch date slips, and the hospital tender you planned around closes without you.

What changes after this course

Your team builds the dossier, the inspection file and the tender response to the standard European reviewers apply, so questions get answered once. You hold a certificate for every learner and a training record per person, ready when an auditor or a partner asks who is trained.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

The Head of Regulatory Affairs stops guessing what the Committee for Medicinal Products for Human Use will ask at day 120. The biosimilarity package follows the European guideline on similar biological medicinal products, the dossier follows the Common Technical Document, and the centralized procedure under Regulation 726/2004 meets the day 120 questions with fewer gaps in the data.

Market access managers answer a national pricing body in the room, with the savings case built for that country rather than copied from the last one. Your sales directors read a tender against the Public Procurement Directive of 2014, fill in the European Single Procurement Document without gaps, and see the disqualifying clause before the deadline instead of after the award notice.

A quality assurance lead walks an inspector through EudraLex Volume 4, Annex 2 on biological products and Annex 16 on batch certification, and answers the cold chain question at the table. Your pharmacovigilance team files serious reports to EudraVigilance inside 15 days, keeps the Risk Management Plan current under Good Pharmacovigilance Practices Module V, and has a plan ready for the first safety signal.

Legal and business development staff date every barrier before a shipment leaves India: the European Patent Register, national Supplementary Protection Certificate records under Regulation 469/2009, and the manufacturing waiver of Regulation 2019/933. Representatives meet Key Opinion Leaders inside the Code of Practice of the European Federation of Pharmaceutical Industries and Associations, and refuse the request that would end up as an anti-bribery case. You also settle who holds the Wholesale Distribution Authorization.

Who needs this training

  • Head of Regulatory Affairs

    The list of questions arrives at day 120 and the biosimilarity gap is in your own dossier. After this course you file the Common Technical Document with the comparability evidence the reviewers look for first.

  • Market Access Manager

    You sit across from a national pricing body that already lists a rival biosimilar. You leave with the price and the Health Technology Assessment answer built for that one country, not for Europe as a whole.

  • Quality Assurance Lead

    An inspector from a European authority opens your batch record and asks about the cold chain from the plant to the port. You answer from Annex 2, Annex 16 and Good Distribution Practice, with the record in front of you.

  • Export Sales Director

    A hospital tender closes on a Thursday and one missing declaration puts your bid out. You read the document for the clause that disqualifies, and you submit a response that scores on supply and quality as well as cost.

  • Head of Pharmacovigilance

    A serious case report from a hospital in Spain reaches your inbox on a Monday morning, and the clock for the report is already running. You know who files it, in which system, and by which day.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: India

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Draft the comparability section of a Marketing Authorization Application and answer a day 120 list of questions from the Committee for Medicinal Products for Human Use.
  2. Prepare a batch record and cold chain file that answers an inspector under Annex 2 and Annex 16 of EudraLex Volume 4.
  3. File a serious adverse reaction report in EudraVigilance within 15 days and keep a Risk Management Plan current.
  4. Date the last patent and Supplementary Protection Certificate barrier for a reference biologic from the European Patent Register and national records.
  5. Score a public tender against the most economically advantageous tender criteria and complete the European Single Procurement Document.
  6. List what a national authority requires for a Wholesale Distribution Authorization and name the Responsible Person for it.
  7. Rank European countries for launch using rival biosimilars, tender dates and payer timelines.

What the company gets

  • Your Indian site meets an inspector with a batch record and cold chain file that already answer the Annex 2 and Annex 16 questions.
  • Your regulatory team sends a dossier whose biosimilarity data answers the questions the Committee for Medicinal Products for Human Use asks, so fewer clock stops eat into your launch date.
  • Your market access and sales staff bring a country-specific price case to each payer and a complete response to each tender, so fewer bids are lost on paperwork.
  • Your legal team knows the Supplementary Protection Certificate date for each country before the first commercial batch leaves India, so the launch plan rests on a checked date.
  • Every learner finishes with a certificate and a per-person training record you can hand to an auditor or a partner.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map the European Biologics and Biosimilars Landscape and pick your targets

    • Why the European Medicines Agency treats your biosimilar as similar, never identical, to the reference.
    • How to see which committees and national agencies touch your product, and in what order.
    • The reference product sales data by country that turns a demand forecast into one your board believes.
  2. 2Clear the Centralized Authorization Procedure with a dossier that holds up

    • What to do when the day 120 list of questions asks for more biosimilarity data than you filed.
    • How to lay out Module 3 and Module 5 of the dossier so the rapporteur finds each answer fast.
    • The comparability package that stops a submission coming back with a major objection.
  3. 3Pass Health Technology Assessment and pricing hurdles with defensible evidence

    • Why central approval does not by itself open hospital doors, because pricing and reimbursement are decided country by country.
    • How to rebuild one price story for each country instead of sending the same dossier to all.
    • The savings argument that moves a Health Technology Assessment body to list your biosimilar.
  4. 4Sequence your biosimilar launches across Europe country by country

    • How to rank countries by rival biosimilars, tender dates and payer speed, then pick your first.
    • Why market protection on the reference product, not your approval date, sets your earliest sale.
    • What to do when one country's payer delay puts the rest of your launch plan at risk.
  5. 5Win over European hospital formularies and Key Opinion Leaders with proof

    • How to answer the consultant who says she prefers the brand she has prescribed for years.
    • The questions a hospital drug and therapeutics committee asks before it adds you to the formulary.
    • Why supply reliability sits beside your comparability data when the committee decides.
  6. 6Pass European Union Good Manufacturing Practice inspections at your site

    • How to walk an inspector through your Indian site so the batch record answers before they ask.
    • The Annex 2 and Annex 16 gaps that draw findings on biological products and Qualified Person release.
    • What to do when the inspector questions your cold chain records for a shipment that left India.
  7. 7Set Up EudraVigilance and Risk Management Plans that meet the deadlines

    • How to build a case-reporting routine that sends serious reports to EudraVigilance within 15 days.
    • The structure the Pharmacovigilance Risk Assessment Committee expects in a Risk Management Plan.
    • What to do when a safety signal on your new biosimilar surfaces in EudraVigilance data.
  8. 8Clear Supplementary Protection Certificates and patents before shipping

    • How to read the European Patent Register and national records to date the last barrier to sale.
    • Why a Supplementary Protection Certificate blocks your sale in Europe, not your plant in India.
    • When the manufacturing waiver lets you build stock in Europe before expiry, and when it does not.
  9. 9Win European public procurement tenders for medicines on more than price

    • How to spot the clause in a tender document that quietly disqualifies a bidder from outside Europe.
    • Why the lowest price can lose when the buyer scores supply and quality as well as cost.
    • The papers that prove your supply chain holds, and where they go in the tender response.
  10. 10Secure Wholesale Distribution Authorization in Europe and hold the cold chain

    • How to choose between your own authorization, a local wholesaler and a logistics partner.
    • What the national authority asks for before it issues a Wholesale Distribution Authorization.
    • What to do when a heatwave or a frozen airport apron puts your 2 to 8 degrees Celsius product at risk.
  11. 11Sell within the Industry Code of Practice and stay clear of bribery concerns

    • How to plan a hospital visit, a congress sponsorship and a speaker fee the Code allows.
    • Which meals, gifts and sponsorships raise anti-bribery questions with European hospital staff.
    • What to do when a physician asks for support that crosses the line, and how to say no in writing.
  12. 12Adapt your biosimilar pipeline to what European payers will fund

    • Which presentations and devices payers favor, and how to build them into your pipeline early.
    • What the 2022 joint European statement on interchangeability lets you tell payers.
    • What to do when a change in European pharmaceutical rules forces you to rework a product in development.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for India, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team